Shilpa Medicare gets initial authorization for Rotigotine Transdermal Patch from Europe [Healthcare]
AI Summary1 min read
TL;DR
Shilpa Medicare has received initial European authorization for its Rotigotine Transdermal Patch, reinforcing its position in the competitive pharmaceutical manufacturing sector.
Tags
Pharmaceuticals & DrugsHealthcareShilpa MedicareRotigotine Transdermal PatchEuropean authorizationpharmaceutical manufacturinghealthcare
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.